Curasight A/S (NGM:CURAS)
Sweden · Delayed Price · Currency is SEK · Price in DKK 19.50
+0.25 (1.30%)
At close: Jul 3, 2026
Curasight Earnings Call Transcripts
Fiscal Year 2025
-
A rights issue seeks up to DKK 100 million to fund pivotal studies in brain and prostate cancer, with about half already secured from investors and management. The capital will extend runway to H2 2026, support key clinical milestones, and enhance partnership opportunities.
Fiscal Year 2024
-
H1 2024 saw increased losses due to higher development activity, but key milestones were achieved, including EMA approval and first patient enrollment in a phase II prostate cancer trial, triggering a milestone payment. A new funding structure could secure up to DKK 120 million, supporting clinical progress and strategic flexibility.